Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus ERY TAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus ERY TAB.
AZASITE vs ERY-TAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic